Behçet's disease--current status.
Sharir
Mordechai
M
Isakov
Itzhak
I
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000175:diagnosis / Q000209:etiology / Q000276:immunology / Q000628:therapy; D002097:C-Reactive Protein / Q000378:metabolism; D004359:Drug Therapy, Combination; D006710:Homocysteine / Q000097:blood; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000150:complications; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D011994:Recombinant Proteins
D020533:Angiogenesis Inhibitors; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D006710:Homocysteine; D002097:C-Reactive Protein; D001379:Azathioprine